Edition:
India

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

1.34USD
16 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.34
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
130,701
52-wk High
$2.95
52-wk Low
$0.88

Chart for

About

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid... (more)

Overall

Beta: 2.92
Market Cap(Mil.): $22.01
Shares Outstanding(Mil.): 21.17
Dividend: --
Yield (%): --

Financials

BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda

* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER

08 May 2018

BRIEF-Oncosec Medical Says Board Determined To Consolidate Roles Of CEO And President

* ONCOSEC MEDICAL INC - BOARD DETERMINED TO CONSOLIDATE ROLES OF CHIEF EXECUTIVE OFFICER AND PRESIDENT

05 May 2018

BRIEF-Oncosec Medical Prices $20 Mln Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 13.3 MILLION COMMON SHARES PRICED AT $1.50PER SHARE Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-OncoSec Medical Announces Proposed Public Offering Of Common Stock

* ONCOSEC MEDICAL INCORPORATED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

01 Feb 2018

BRIEF-OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

* ONCOSEC PROVIDES ENCOURAGING CLINICAL OBSERVATIONS RELATED TO TRIPLE NEGATIVE BREAST CANCER STUDY Source text for Eikon: Further company coverage:

18 Jan 2018

Earnings vs. Estimates